Nestlé puts down $40M, kicks off deal with gut microbiome specialist to fight food allergies
French company Enterome, which works with the microbiome, has scored $40 million in a wide-ranging deal with its long-time Swiss investor Nestlé Health Science to co-develop an oral pill for food allergies that’s on the cusp of entering the clinic.
“Today, we believe that we have reached a level where we understand what the bacteria living in the human gut are able to produce,” said Pierre Belichard, CEO of Enterome.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.